S-1/A: CEL-SCI Files S-1/A for $13.7M Common Stock Offering

CEL-SCI Corporation has filed an amendment to its registration statement to raise approximately $13.7 million through a best-efforts offering of common stock and pre-funded warrants.

Summary

• The company is offering up to 4,885,993 shares of common stock and corresponding pre-funded warrants.
• The assumed public offering price is $3.07 per share, based on the April 30, 2026 closing price.
• Net proceeds are estimated at $13.7 million, intended for the continued development of its lead immunotherapy candidate, Multikine, and general corporate purposes.
• The offering is conducted on a best-efforts basis with no minimum requirement for closing.
• The offering will terminate on September 30, 2026, unless extended or completed earlier.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a high-risk capital raise necessitated by the company's ongoing operating losses and the need to fund a confirmatory clinical trial to validate its lead asset.

Positives

• Phase III clinical trial data for Multikine in the target population showed a 73% 5-year survival rate compared to 45% in the control group.
• The hazard ratio for the target population was 0.35, indicating a significant reduction in the risk of death.
• No significant safety signals or toxicities were observed in approximately 740 patients across clinical trials.
• The FDA has indicated that the company may proceed with a confirmatory registration study in the identified target population.

Negatives

• The company has no products currently approved for sale and has incurred significant losses to date.
• Management has identified conditions that raise substantial doubt about the company's ability to continue as a going concern.
• The company reported an operating loss of $24.8 million for the fiscal year ended September 30, 2025.
• The offering will result in immediate and substantial dilution of approximately $1.16 per share for new investors.

Risks

• Heavy dependence on the success of a single product candidate, Multikine.
• Uncertainty regarding regulatory approval and the potential for costly, time-consuming clinical trials.
• Reliance on third-party contract research organizations (CROs) for clinical trial execution.
• Potential for future dilution through additional equity or convertible debt offerings.
• Material weaknesses in internal control over financial reporting as of September 30, 2025.
• Geopolitical risks and international operational challenges.

Future Outlook

The company plans to initiate a 212-patient confirmatory Phase III registration study for Multikine in the target population, with full enrollment expected 18-24 months after commencement, aiming for early approval thereafter.

Management Comments

• The company believes Multikine significantly extended life in the target patient population.
• Management believes the confirmatory study has a high likelihood of success based on prior Phase III data.
• The company intends to seek accelerated or conditional approval in the new target population.

Industry Context

StockSavvy.ai notes that CEL-SCI is attempting to differentiate its immunotherapy by targeting low PD-L1 expression, a segment often underserved by major checkpoint inhibitors like Keytruda, which typically target high PD-L1 expression.

Comparison to Industry Standards

• Keytruda (Merck) is approved for high PD-L1 head and neck cancer, whereas Multikine targets low PD-L1 patients.
• The company's 5-year survival rate of 73% in the target population is positioned as superior to the standard of care (45%) observed in their study.
• The company's regulatory strategy relies on conditional approval pathways similar to those used by other late-stage biotech firms.

Corporate Governance

Legal Proceedings

• None disclosed in the filing.

Related Party Transactions

• The filing notes various stock purchases by the CEO and directors between 2024 and 2026.

Stakeholder Impact

• Existing shareholders face immediate dilution from the new share issuance.
• Investors in the offering face high risks associated with clinical development and the company's going concern status.

Next Steps

• Commence the 212-patient confirmatory Phase III registration study.
• Identify and collaborate with a diagnostic partner for a companion diagnostic test.
• Perform a bridging study for the PD-L1 assay.

Key Dates

Recommendation

The stock is highly speculative given the company's going concern status and reliance on a single clinical asset; investors should wait for concrete progress on the confirmatory trial before increasing exposure.

Keywords

CEL-SCI, CVM, Multikine, Immunotherapy, Biotechnology, Head and Neck Cancer, Clinical Trials, Equity Offering